Northland Securities Predicts Reduced Earnings for Indivior

Indivior PLC (NASDAQ:INDV) – Equities researchers at Northland Securities cut their Q4 2026 earnings per share estimates for shares of Indivior in a research note issued to investors on Thursday, February 26th. Northland Securities analyst C. Byrnes now expects that the company will post earnings of $0.70 per share for the quarter, down from their previous estimate of $0.71. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

Several other equities research analysts have also recently commented on INDV. Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. HC Wainwright upped their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Finally, Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Indivior currently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Trading Down 3.5%

Shares of INDV opened at $30.87 on Monday. The stock has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.82 and a beta of 0.83. Indivior has a 12 month low of $8.64 and a 12 month high of $38.00. The firm has a fifty day simple moving average of $34.35 and a 200 day simple moving average of $30.21.

Indivior (NASDAQ:INDV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The company had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million.

Insider Buying and Selling

In other Indivior news, Director Mark Stejbach purchased 775 shares of the stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director directly owned 16,847 shares in the company, valued at $596,215.33. This represents a 4.82% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara Ryan acquired 775 shares of the company’s stock in a transaction on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 4,871 shares of company stock worth $172,385 in the last 90 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Indivior in the 2nd quarter worth about $855,000. Federated Hermes Inc. acquired a new stake in shares of Indivior in the third quarter valued at approximately $8,120,000. Aberdeen Group plc bought a new stake in shares of Indivior in the third quarter valued at approximately $3,875,000. Pacer Advisors Inc. bought a new stake in shares of Indivior in the third quarter valued at approximately $9,086,000. Finally, Acadian Asset Management LLC grew its position in Indivior by 124.4% during the second quarter. Acadian Asset Management LLC now owns 1,492,272 shares of the company’s stock worth $21,977,000 after buying an additional 827,230 shares in the last quarter. 60.33% of the stock is owned by institutional investors and hedge funds.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.